B. Hasan

V. Durieux, A. Dingemans, S. Novello, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

C. Dooms, N. Girard, H. Gietema, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03).

V. Torri, G. Scagliotti, R. Gaafar, 2010 .

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

N. Girard, S. Lantuejoul, S. Novello, 2018, European journal of cancer.

Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.

M. Weichenthal, J. Becker, R. Dummer, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Major achievements of the EORTC Cutaneous Lymphoma Task Force (CLTF)

D. Lacombe, R. Dummer, S. Whittaker, 2012 .

Efficacy and safety of bexarotene combined with psoralen–ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB–IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00056056)

R. Dummer, S. Whittaker, B. Meulemans, 2012, The British journal of dermatology.

De ﬁ ning Synchronous Oligometastatic Non – Small Cell Lung Cancer: A Systematic Review

V. Durieux, S. Novello, T. Berghmans, 2022 .

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.

N. Girard, S. Lantuejoul, S. Novello, 2019, European journal of cancer.

MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion

C. Dooms, D. de Ruysscher, A. Dingemans, 2018, Journal of Thoracic Oncology.

MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts

N. Girard, H. Gietema, G. Scagliotti, 2018, Journal of Thoracic Oncology.

MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC

N. Girard, A. Dingemans, S. Lantuejoul, 2018, Journal of Thoracic Oncology.

Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).

E. Smit, J. V. van Meerbeeck, P. Baas, 2016, European journal of cancer.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

L. Seymour, K. Ding, F. Shepherd, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.

C. Dooms, D. de Ruysscher, S. Novello, 2019, European journal of cancer.

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

C. Fink, A. Dingemans, J. V. van Meerbeeck, 2011, European journal of cancer.

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

S. Novello, R. Dziadziuszko, T. Berghmans, 2017, Clinical lung cancer.

Biomarkers for Malignant Pleural Mesothelioma

P. Baas, B. Hasan, J. Welch, 2008, Molecular Diagnosis & Therapy.

A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs

R. Cowan, J. Scarisbrick, S. Whittaker, 2017, European Journal of Dermatology.

Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.

A. Dingemans, S. Novello, C. Faivre-Finn, 2019, Lung cancer.

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

J. V. van Meerbeeck, A. Price, P. Baas, 2013, European journal of cancer.

Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10.

L. Seymour, R. Livingston, K. Ding, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century

L. Collette, T. Gorlia, S. Litière, 2012 .

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).

R. V. van Klaveren, V. Torri, G. Scagliotti, 2011, European journal of cancer.

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.

U. Dafni, R. Stahel, M. Guillot, 2021, Lung cancer.

A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

L. Livi, M. Mauer, T. Berghmans, 2020 .

Attitudes and referral patterns of lung cancer specialists in Europe to Specialized Palliative Care (SPC) and the practice of Early Palliative Care (EPC)

M. O'Brien, H. Charalambous, B. Hasan, 2014, BMC Palliative Care.

3023 Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network

N. Girard, B. Besse, J. Menis, 2015 .

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

V. Georgoulias, P. Baas, T. Čufer, 2015, European journal of cancer.

Adjuvant chemotherapy in elderly patients: An analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10.

L. Seymour, R. Livingston, K. Ding, 2006, Journal of Clinical Oncology.

Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer

E. Stathopoulos, V. Georgoulias, J. Souglakos, 2019, The Pharmacogenomics Journal.